Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 13 01 2022
accepted: 06 04 2022
pubmed: 14 5 2022
medline: 16 9 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

KRAS mutations (KRAS Information on molecular features was available for 2349 incident CRC cases within the Netherlands Cohort Study (NLCS), with complete covariate data available for 1934 cases and 3911 subcohort members. Multivariable-adjusted Cox-regression was used to estimate associations of energy balance-related factors with risk of CRC based on individual molecular features (KRAS In men, BMI and clothing-size were positively associated with risk of colon, but not rectal cancer, regardless of molecular features subgroups; the strongest associations were observed for PIK3CA In men, associations did not vary according to molecular features. In women, a role of KRAS mutations in the etiological pathway between adiposity and colon cancer is suggested, and of PIK3CA mutations between physical activity and colon cancer.

Identifiants

pubmed: 35546360
doi: 10.1007/s00432-022-04019-9
pii: 10.1007/s00432-022-04019-9
pmc: PMC9470639
doi:

Substances chimiques

KRAS protein, human 0
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2723-2742

Subventions

Organisme : KWF Kankerbestrijding
ID : 11044

Informations de copyright

© 2022. The Author(s).

Références

J Transl Med. 2013 Nov 21;11:293
pubmed: 24256736
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Epidemiol Biomarkers Prev. 2022 Mar 01;31(3):633-646
pubmed: 34933957
Epidemiology. 2009 Sep;20(5):673-6
pubmed: 19451821
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Int J Cancer. 2019 Jul 15;145(2):327-337
pubmed: 30613980
PLoS One. 2014 Jun 11;9(2):e98964
pubmed: 24918610
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47
pubmed: 18086756
Mol Cell Proteomics. 2016 Sep;15(9):2924-38
pubmed: 27340238
Semin Oncol. 2007 Dec;34(6):546-54
pubmed: 18083378
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1867-1874
pubmed: 34272264
Obes Rev. 2009 Nov;10(6):610-6
pubmed: 19527447
Radiother Oncol. 2009 Sep;92(3):329-33
pubmed: 19604589
J Clin Epidemiol. 1990;43(3):285-95
pubmed: 2313318
Clin Cancer Res. 2015 Apr 15;21(8):1828-34
pubmed: 25878364
Int J Epidemiol. 1990 Sep;19(3):553-8
pubmed: 2262247
Carcinogenesis. 2008 Sep;29(9):1765-73
pubmed: 18339680
Ann Oncol. 2018 Apr 1;29(4):825-834
pubmed: 29438474
J Clin Pathol. 2016 Jan;69(1):35-41
pubmed: 26350752
J Natl Cancer Inst. 2010 Mar 17;102(6):391-400
pubmed: 20208017
J Hematol Oncol. 2018 Dec 14;11(1):139
pubmed: 30547809
J Cancer. 2020 Apr 6;11(13):3827-3833
pubmed: 32328187
Cancer Treat Rev. 2016 Sep;49:57-64
pubmed: 27501018
Am J Clin Nutr. 2020 Mar 1;111(3):562-569
pubmed: 31897467
Clin Transl Gastroenterol. 2017 Apr 27;8(4):e91
pubmed: 28448072
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2303-11
pubmed: 24127414
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Am J Clin Nutr. 2002 Apr;75(4):683-8
pubmed: 11916754
Mutat Res. 2001 Nov 1;483(1-2):73-81
pubmed: 11600135
Science. 2010 Dec 3;330(6009):1340-4
pubmed: 21127244
Mod Pathol. 2002 Jul;15(7):741-9
pubmed: 12118112
Int J Epidemiol. 2012 Aug;41(4):1060-72
pubmed: 22531127
J Pathol Clin Res. 2022 Mar;8(2):169-180
pubmed: 34791830
Am J Epidemiol. 2013 Mar 15;177(6):514-30
pubmed: 23420352
J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6
pubmed: 11078760
Int J Cancer. 2007 Feb 1;120(3):656-63
pubmed: 17096326
Br J Cancer. 2009 Feb 24;100(4):611-6
pubmed: 19209175
Colorectal Dis. 2005 May;7(3):204-13
pubmed: 15859955
Eur J Cancer Prev. 2013 Nov;22(6):492-505
pubmed: 23591454
BMC Cancer. 2010 Mar 16;10:101
pubmed: 20233444
Int J Cancer. 2016 Aug 15;139(4):854-68
pubmed: 27037951

Auteurs

Josien C A Jenniskens (JCA)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands.

Kelly Offermans (K)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands.

Colinda C J M Simons (CCJM)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands.

Iryna Samarska (I)

Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 5800, 6202 AZ, Maastricht, The Netherlands.

Gregorio E Fazzi (GE)

Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 5800, 6202 AZ, Maastricht, The Netherlands.

Jaleesa R M van der Meer (JRM)

Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 5800, 6202 AZ, Maastricht, The Netherlands.

Kim M Smits (KM)

Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 5800, 6202 AZ, Maastricht, The Netherlands.

Leo J Schouten (LJ)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands.

Matty P Weijenberg (MP)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands.

Heike I Grabsch (HI)

Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 5800, 6202 AZ, Maastricht, The Netherlands. h.grabsch@maastrichtuniversity.nl.
Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. h.grabsch@maastrichtuniversity.nl.

Piet A van den Brandt (PA)

Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, P.O. BOX 616, 6200 MD, Maastricht, The Netherlands. pa.vandenbrandt@maastrichtuniversity.nl.
Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, The Netherlands. pa.vandenbrandt@maastrichtuniversity.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH